OrbiMed’s Kiniksa Pharmaceuticals KNSA Stock Holding History

OrbiMed’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.7M	Sell	180,599 -6,600	-4%	-$292K	0.17%	81
2025 Q4	$7.72M	Buy	+187,199	New	+$7.51M	0.16%	86

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

OrbiMed's KNSA Position: Q1 2026 in Review

OrbiMed reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.5% in Q1 2026, selling an estimated $292K and leaving 180,599 shares worth $8.7M. The position accounts for 0.17% of the portfolio, ranked #81.

OrbiMed first reported a position in KNSA in Q4 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

OrbiMed held 180,599 shares of Kiniksa Pharmaceuticals worth $8.7M as of Q1 2026.
OrbiMed sold 6,600 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $292K.
Kiniksa Pharmaceuticals made up 0.17% of OrbiMed's portfolio in Q1 2026, its #81 holding.
OrbiMed first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.